

8th August 2018 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

CannPal Enters MOU with The University of Melbourne to Research Epilepsy Treatment for Dogs

Key Highlights

- CannPal has entered into a Memorandum of Understanding with The University of Melbourne for veterinary research
- CannPal and the University will work towards a pilot study to determine cannabidiol's efficacy in the treatment of epilepsy in dogs
- The MOU builds on CannPal's current research pipeline which includes the Phase 1B study for CPAT-01, a pain control in dogs, and its extension CPAT-01C for cats.

8th August 2018: Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has entered into a Memorandum of Understanding (MOU) with The University of Melbourne ('the University') to broaden the Company's research pipeline.

Under the terms of MOU, CannPal and the University will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs in 2019. Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, antiinflammatory, antibacterial and antiseizure properties.

In June 2018, the U.S Food and Drug Administration approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy in human patients of 2 years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana and the Company is hopeful that similar effects using cannabinoids can be seen in dogs with idiopathic epilepsy.

The MOU with the University hopes to build on CannPal's strong research pipeline which is being led by Dr Margaret Curtis, an alumnus of global animal health company Elanco.

CannPal's Founder and Managing Director Layton Mills:

"This MOU with the University of Melbourne is the latest in a long line of strategic agreements CannPal has entered, to establish the Company as a global leader in cannabinoid-derived therapeutics for companion animals. Its further validation of the high-quality research we are undertaking and we look forward to working with the University on this project"

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is



researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals. To learn more please visit: www.cannpal.com

ENDS

For further information, please contact:

CannPal
Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Media enquiries
Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

 @CannPalAT

 facebook.com/CannPal

